Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma: Single Technology Appraisal Evidence Assessment Group report

Mark Stephen Corbett; Ana Isabel Duarte; Simon Mark Walker; Kath Wright; Mark Crawford Simmonds; Stephen John Palmer

Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma: Single Technology Appraisal Evidence Assessment Group report

Mark Stephen Corbett, Ana Isabel Duarte, Simon Mark Walker, Kath Wright, Mark Crawford Simmonds, Stephen John Palmer

Research output: Book/Report › Commissioned report

Original language	English
Commissioning body	National Institute for Health and Care Excellence
Number of pages	609
Publication status	Published - 2018

Access to Document

https://www.nice.org.uk/guidance/gid-ta10269/documents/committee-papers

Cite this

@book{70b0b06d89ff42eb982f019f88997189,

title = "Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma: Single Technology Appraisal Evidence Assessment Group report",

author = "Corbett, {Mark Stephen} and Duarte, {Ana Isabel} and Walker, {Simon Mark} and Kath Wright and Simmonds, {Mark Crawford} and Palmer, {Stephen John}",

year = "2018",

language = "English",

}

TY - BOOK

T1 - Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma

T2 - Single Technology Appraisal Evidence Assessment Group report

AU - Corbett, Mark Stephen

AU - Duarte, Ana Isabel

AU - Walker, Simon Mark

AU - Wright, Kath

AU - Simmonds, Mark Crawford

AU - Palmer, Stephen John

PY - 2018

Y1 - 2018

M3 - Commissioned report

BT - Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma

ER -